

Reference:	FOI.5042.21
Subject:	Use of Bevacizumab
Date of Request:	18 January 2021

Requested:

Could you please provide answers to the following two questions about the usage of the drug Bevacizumab:

1. How many patients have been treated by your trust (for any medical condition) in the past 6 months with Bevacizumab?
2. Please provide the number of patients treated in the past 6 months with Bevacizumab for the following conditions:
 - Colorectal cancer
 - Breast cancer
 - Renal cell carcinoma
 - Non-small cell lung cancer
 - Ovarian cancer (epithelial, fallopian tube or primary peritoneal)
 - Carcinoma of the cervix

Response:

Hywel Dda University Healthy Board (UHB) is unable to provide you with the exact number of patients treated with Bevacizumab or the condition it was prescribed for, due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.